Bridgepoint Europe VII, through its fund Bridgepoint fund, has revealed a strategic investment in RoC Skincare, marking the fund’s sixth acquisition in the dermatology ecosystem. In this deal, Gryphon Investors, RoC’s existing backer, will transfer its majority stake to Bridgepoint in a transaction with an undisclosed value.
This move underscores Bridgepoint’s commitment to supporting businesses within the dermatology sector, building upon its successful engagements with companies like Vivacy and HTL. The acquisition positions Bridgepoint as a key player in the growing skincare market.
Fernando Acosta, CEO of RoC Skincare, expressed optimism about the partnership, stating, “With Bridgepoint’s deep expertise in the dermatology sector and its strong European presence, RoC is poised to capitalize on the promising growth opportunities that lie ahead.” Acosta extended gratitude to both the RoC team and Gryphon Investors for their support, highlighting the brand’s evolution into one of the largest independent skincare entities globally. He emphasized their dedication to providing clinically proven skin health solutions.
The acquisition aligns with Bridgepoint’s strategy to leverage its knowledge and European network in the dermatology sector, signaling a commitment to fostering RoC Skincare’s continued success in the competitive skincare market. The transaction marks another milestone in Bridgepoint’s journey of strategic investments within the broader dermatology ecosystem.
